Would you avoid risankizumab in a patient with stricturing Crohn’s complicated by granulomatous bronchiolitis with stenosis who had to stop ustekinumab due to hemoptysis?

Unless there had been a rapid and dramatic beneficial response of the Crohn’s disease to ustekinumab, I would have little appetite for trying another IL-blocker. A different mechanism, like JAK, might be worth trying, but the serious pulmonary complication probably warrants steroid therapy. One coul...